



Exploring the Link Between Statins and Smoking Cessation

ARTICLE INFO

Article Type

Narrative Review

Authors

Nilofar Aghajani¹

Hossein Azizi^{1,2}

Saeed Semnanian^{1,3,*}

1- Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

2- Institute for Brain and Cognition, Tarbiat Modares University, Tehran, Iran

3- School of Cognitive Sciences, Institute for Research in Fundamental Sciences, IPM, Tehran, Iran

*Corresponding author:

Saeed Semnanian,

Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

ssemnan@modares.ac.ir

<https://orcid.org/0000000289873291>

ABSTRACT

Cigarette smoking remains a significant public health concern despite established cessation programs and their limited success rates. This persistent struggle compels us to explore innovative solutions. This review examines the potential of statins, the cholesterol-lowering medications, as a novel weapon in the fight against smoking addiction.

Statins might offer a novel intervention for smoking cessation by potentially addressing two key aspects of addiction, inflammation, and the reward system. Addiction is often linked to chronic brain inflammation. Statins, with their potential anti-inflammatory properties, could dampen this inflammatory response, potentially weakening the addictive cycle of smoking. Additionally, they might influence the brain's reward system, which plays a crucial role in nicotine dependence. Dopamine, a neurotransmitter heavily involved in reward processing, is a key player. Nicotine triggers dopamine release, leading to pleasurable sensations that reinforce smoking behavior. This review suggests that statins might also modulate dopamine signaling, potentially reducing the pleasurable effects of nicotine, and reducing cravings.

Keywords: nicotine, statin, addiction, craving, relapse

Copyright© 2020, TMU Press. This open-access article is published under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License which permits Share (copy and redistribute the material in any medium or format) and Adapt (remix, transform, and build upon the material) under the Attribution-NonCommercial terms

INTRODUCTION

Tobacco use persists as a significant global health crisis, resulting in millions of deaths annually (1). Despite extensive interventions such as warnings, prohibitions, and taxation, more than 1.3 billion individuals continue to smoke. Projections suggest a worrisome scenario of 10 million deaths per year by 2025 if current trends persist (2,3). This emphasizes the urgent necessity to develop innovative and efficacious strategies to address this detrimental addiction.

Tobacco consumption casts a profound impact on global health, claiming millions of lives each year (2). Nicotine, the primary addictive agent, produces the patterns of compulsive use and

relapse among individuals struggling with addiction (3). During therapy, counseling, and smoking cessation medications offer support, and many individuals remain trapped in a frustrating cycle of relapse (4). This review explores an intriguing prospect: can statins, known for their cholesterol-lowering properties, emerge as a new tool in the battle against nicotine addiction?

Potential mechanisms of action

The influence of nicotine on the brain is like a sticky network, trapping users in a persistent cycle of cravings and relapse. This complex network maintains the craving and relapse cycle. Neuroinflammation, a state of low-grade inflammation associated with reward and

motivation centers, contributes to the construction of this web. Interestingly, statins, initially recognized for their ability to reduce LDL cholesterol levels, may possess anti-inflammatory properties. Could these properties disrupt the cycle of nicotine addiction? (5). Preliminary studies suggest a plausible correlation. Individuals prescribed statins exhibit diminished levels of inflammatory markers in their brain tissues, implying a potential influence on susceptibility to addiction (6).

Recent studies have shown that statins exhibit anti-inflammatory properties in brain tissue, with evidence from animal models demonstrating a reduction in microglial activation through Toll-like receptor 4 (TLR4) modulation (7). Additionally, research on cerebral ischemia/reperfusion injury in rats has revealed that atorvastatin exerts neuroprotective effects by inhibiting the TLR4/NF-κB signaling pathway and mitigating inflammation (8). Moreover, in a rabbit model of spinal cord ischemia-reperfusion injury, rosuvastatin treatment was associated with a decrease in inflammation, oxidative stress, and neuronal apoptosis, suggesting a potential neuroprotective role for statins in inflammatory conditions (9).

Moreover, nicotine manipulates the brain's dopamine system, often referred to as the "reward

pathway". When nicotine triggers a dopamine surge, it elicits pleasurable sensations, which keeps people continued use. Nevertheless, emerging research proposes that statins may interfere with dopamine signaling in the brain, potentially lowering the likelihood of relapse, and reducing cravings. Some studies indicate that statins could modulate nicotinic acetylcholine receptors (nAChRs) receptors, potentially attenuating the pleasurable effects of nicotine. Imagine them like roadblocks on the craving highway, making it harder for nicotine to deliver its effects. Consider statins as obstacles along the reward pathway, further impeding nicotine's capacity to induce pleasurable effects. However, further research is needed to fully understand the specific interactions between statins and nAChRs (nicotinic acetylcholine receptors) in the context of nicotine addiction (10,11) (Fig. 1).

The current landscape: a beam of hope, need for clarity

The potential mechanisms by which statins might influence nicotine dependence, as discussed earlier, illuminate a beam of hope for future research and development. Their potential anti-inflammatory properties and ability to modulate the brain's reward system suggest a novel approach to tackling addiction. However, translating this promise into clinical practice




Figure 1: Known mechanisms of statins (12-15).

requires well-designed and rigorous studies to definitively assess the efficacy of statins for smoking cessation.

Current research on statins and smoking cessation presents several limitations. Observational studies, which form a significant portion of the existing evidence base, are unable to establish cause-and-effect relationships. Smokers who use statins might differ from non-smokers in various health aspects, potentially influencing the observed outcomes. Additionally, these studies often suffer from methodological limitations that restrict the generalizability of their findings to the broader population of smokers. These limitations might include, for example, small sample sizes or short follow-up periods.

These limitations highlight the critical need for large-scale, randomized controlled trials (RCTs) specifically designed to evaluate the impact of statins on smoking cessation rates. Ideally, such trials would involve long-term follow-up to assess the durability of any observed benefits. By incorporating robust methodologies and addressing the limitations of past research, RCTs can provide definitive evidence regarding the potential role of statins in smoking cessation strategies (12).

Charting the path forward: revealing the prospects of statins

The potential interaction between statins and nicotine addiction requires further investigation. Here are key focal points for future investigation:

Statins as a critical component in solving the puzzle: a comprehensive examination

Imagine finally having a clear picture of how statins might help people quit the smoking habit. To get there, we need big studies with tons of randomly chosen volunteers. These studies would be like real-world experiments, evaluating not only initial cessation rates but also the impact of statins on cravings, withdrawal symptoms, and the likelihood of relapse.

Unleashing the full potential of statins in combating nicotine addiction hinges on well-designed, large-scale clinical trials. Imagine a future where we possess a crystal-clear understanding of how these medications aid

smokers in kicking the habit. To achieve this, we require extensive studies involving a multitude of volunteers, randomly selected to ensure unbiased results. These studies wouldn't be confined to laboratory settings; they would mirror real-world scenarios, meticulously evaluating not just the initial success rates in quitting smoking but also the long-term effects of statins on cravings, withdrawal symptoms, and the ever-present threat of relapse (12,13). However, a crucial factor to consider in designing such studies is the type of statin utilized. Because only statins capable of traversing the Blood-Brain Barrier (BBB) can exert their influence on brain pathways associated with addiction, future research should specifically focus on these BBB-penetrating statins (14). This targeted approach will provide a much clearer picture of their effectiveness in curbing nicotine addiction and pave the way for the development of a powerful tool in the fight against smoking (15).

Unveiling the statin secret nicotine addiction

To enhance future treatment modalities, it is imperative to unravel the mechanism through which statins combat addiction. This means diving into the science behind the scenes. Scientists assume the role of investigators, probing into phenomena such as neuroinflammation (which is associated with addiction), dopamine signaling (the brain's reward system exploited by nicotine), and the potential interactions between statins and nicotinic acetylcholine receptors (crucial sites where nicotine binds in the brain). Through a comprehensive understanding of the complex interactions driving nicotine addiction, tailored therapeutic approaches can be developed to effectively target and exploit the vulnerabilities inherent in addiction (16,17).

Personalized treatment strategies

Nicotine addiction exhibits substantial individual variations in its manifestation. The pronounced individual heterogeneity observed in nicotine addiction highlights the drawbacks of a standardized treatment approach. This realization is driving a paradigm shift in smoking cessation strategies, with a growing emphasis on personalized treatment plans. Imagine a scenario

wherein healthcare providers can thoroughly investigate each patient's distinctive biological and psychological profile. By comprehending their specific risk factors and susceptibilities, healthcare providers can then customize interventions to address their individual needs. This person-centered approach brings immense promise for optimizing treatment efficacy and achieving sustained abstinence. Ongoing research on the potential role of statins in managing nicotine dependence further highlights the possibilities of personalized medicine in smoking cessation. Future research could explore if statins could become an adjunctive tool used alongside existing therapies. Ideally, this would enable healthcare professionals to create personalized strategies for smoking cessation based on individual risk factors and treatment responsiveness (18,19).

For example, individual genetic variations in metabolic pathways have been found to influence the effectiveness of statins in reducing nicotine dependence in some people. This personalized approach could pave the way for more targeted and efficient smoking cessation interventions among diverse populations.

CONCLUSION

The devastating consequences of smoking are undeniable. Irrefutable evidence links it to a multitude of cancers and wreaks havoc on various organs. Healthcare providers hold a vital responsibility: identifying smoking patients and offering them comprehensive, evidence-based cessation advice. Smoking not only shortens lives but diminishes their quality. Integrating smoking cessation strategies into every clinical encounter, particularly cardiovascular risk management, is paramount. Effective and safe pharmacological interventions should be readily available to all smokers who yearn to quit. It's never too late to break free – quitting smoking can turn the tide on smoking-related morbidity and mortality.

This review ushers in a new era of hope. Statins, traditionally used for cholesterol control, present a potential game-changer in the fight against smoking. Their two-pronged attack – mitigating addiction-linked inflammation and fine-tuning dopamine signaling – holds immense promise for weakening nicotine's grip. While

initial studies ignite optimism, meticulously designed trials and research into the underlying mechanisms are crucial. By addressing the limitations of current research and venturing down this exciting new path, we can unlock a deeper understanding of statins' capacity to combat nicotine addiction. This knowledge has the potential to empower individuals to shatter the chains of addiction and reclaim their health, echoing the sentiment of emerging therapeutic options on the horizon. With a renewed perspective and continued research, we can make smoking a relic of the past.

By addressing the limitations of current research paradigms and venturing down these exciting new paths, we can unlock a deeper understanding of statins' capacity in treating nicotine addiction. This knowledge has the potential to empower individuals in breaking free from the cycle of addiction and reclaiming their well-being.

ACKNOWLEDGEMENT

This work was supported by the Cognitive Sciences and Technologies Council of Iran, The Iran National Science Foundation (INSF) and the Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

DECLARATIONS

Authors have no conflict of interest to declare.

REFERENCES

- [1] Lydon DM, Wilson SJ, Child A, Geier CF. Adolescent Brain Maturation and Smoking: What We Know and Where We're Headed. *Neurosci Biobehav Rev.* 2014 Sep;45:323–42.
- [2] Tobacco [Internet]. [cited 2024 May 18]. Available from: <https://www.who.int/health-topics/tobacco>
- [3] Benowitz NL. Nicotine addiction. *N Engl J Med.* 2010 Jun 17;362(24):2295–303.
- [4] Park SK, Yun DH, Chung JY, Kong Y, Cho SY. The 10 kDa protein of *Taenia solium* metacystodes shows genus specific antigenicity. *Korean J Parasitol.* 2000 Sep;38(3):191–4.
- [5] Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuroinflammation: The role and consequences. *Neurosci Res.* 2014 Feb 1;79:1–12.

- [6] Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet Lond Engl*. 2000 Nov 11;356(9242):1627–31.
- [7] Van Der Putten C, Kuipers HF, Zuiderwijk-Sick EA, Van Straalen L, Kondova I, Van Den Elsen PJ, et al. Statins amplify TLR-induced responses in microglia via inhibition of cholesterol biosynthesis. *Glia*. 2012;60(1):43–52.
- [8] Neuroprotective Effects of Rosuvastatin in Spinal Cord Ischemia-Reperfusion Injury in Rabbits [Internet]. [cited 2024 Jun 13]. Available from: https://www.researchgate.net/publication/271656555_Neuroprotective_Effects_of_Rosuvastatin_in_Spinal_Cord_Ischemia-Reperfusion_Injury_in_Rabbits
- [9] Yang JW, Hu ZP. Neuroprotective effects of atorvastatin against cerebral ischemia/reperfusion injury through the inhibition of endoplasmic reticulum stress. *Neural Regen Res*. 2015 Aug;10(8):1239–44.
- [10] Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. *Am J Med*. 2008 Apr;121(4 Suppl 1):S3-10.
- [11] Stein EA, Pankiewicz J, Harsch HH, Cho JK, Fuller SA, Hoffmann RG, et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. *Am J Psychiatry*. 1998 Aug;155(8):1009–15.
- [12] Statins: Actions, side effects, and administration - UpToDate [Internet]. [cited 2024 May 27]. Available from: <https://www.uptodate.com/contents/statins-actions-side-effects-and-administration>
- [13] Ingrand I, Solinas M, Ingrand P, Dugast E, Saulnier PJ, Péroul-Pochat MC, et al. Lack of effects of simvastatin on smoking cessation in humans: A double-blind, randomized, placebo-controlled clinical study. *Sci Rep*. 2018 Mar 1;8:3836.
- [14] Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. *J Alzheimers Dis JAD*. 2011;23(2):307–18.
- [15] Chauvet C, Nicolas C, Lafay-Chebassier C, Jaber M, Thiriet N, Solinas M. Statins Reduce the Risks of Relapse to Addiction in Rats. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol*. 2016 May;41(6):1588–97.
- [16] D’Souza MS, Markou A. Neuronal Mechanisms Underlying Development of Nicotine Dependence: Implications for Novel Smoking-Cessation Treatments. *Addict Sci Clin Pract*. 2011 Jul;6(1):4–16.
- [17] Picciotto MR, Kenny PJ. Mechanisms of Nicotine Addiction. *Cold Spring Harb Perspect Med*. 2021 May;11(5):a039610.
- [18] Heilig M, MacKillop J, Martinez D, Rehm J, Leggio L, Vanderschuren LJM. Addiction as a brain disease revised: why it still matters, and the need for consilience. *Neuropsychopharmacology*. 2021 Sep;46(10):1715–23.
- [19] Print. Mayo Clinic. [cited 2024 May 18]. Nicotine Dependence Center - Overview. Available from: <https://www.mayoclinic.org/departments-centers/nicotine-dependence-center/sections/overview/ovc-20457521>